Autobahn Therapeutics, a clinical-stage biotechnology company advancing restorative therapies for individuals living with neuropsychiatric and neuroimmunologic disorders, today announced the presentation of new preclinical data supporting its lead investigational compound, elunetirom, at the 64th Annual American College of Neuropsychopharmacology Annual…
Axelspace Corporation, a Japanese microsatellite developer and operator guided by its mission of “Space at Your Fingertips,” has entered into a memorandum of understanding (MoU) with Jethi Software Development PLC, an Ethiopian technology firm, to collaborate on addressing pressing social…
Agenus Inc. , a leader in immuno-oncology innovation, announced the completion of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd., a transaction designed to accelerate the global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) combination immunotherapy…
Almirall, a global pharmaceutical company focused exclusively on medical dermatology, has announced plans to initiate a Phase III clinical study evaluating the efficacy and safety of lebrikizumab in adult patients with nummular eczema. The study, named LumiNE, is scheduled to…
Integrated DNA Technologies Expands Synthetic Biology Portfolio Through Strategic Collaboration with Ansa Biotechnologies Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics, has announced a strategic collaboration with Ansa Biotechnologies, Inc., a pioneering company in DNA…
BridgeBio Pharma, Inc., a biopharmaceutical company focused on developing treatments for genetic diseases, announced plans to advance its long-term balance sheet strategy through a significant new financing initiative. The company disclosed that it intends to offer $550 million in aggregate…
Celltrion delivered a comprehensive update on its long-term growth strategy and next-generation therapeutic portfolio during the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco, California. The global biopharmaceutical leader outlined major advances across its innovative drug pipeline—including antibody-drug…
China Approves Sanofi-Licensed Medicines Myqorzo and Redemplo, Expanding Treatment Options for Rare and Complex Diseases China’s National Medical Products Administration (NMPA) has granted regulatory approval to two innovative medicines licensed by Sanofi—Myqorzo (aficamten) and Redemplo (plozasiran). The approvals mark an…
Johnson & Johnson Launches Arbrea Breast Simulator Surgeon App for Mentor in the U.S. Johnson & Johnson has announced the U.S. launch of the Arbrea Breast Simulator Surgeon App for Mentor, a digital consultation tool designed to support plastic surgeons…
Johnson & Johnson Announces Positive Phase 3 Results for TECVAYLI® Monotherapy in Early Relapse Multiple Myeloma Johnson & Johnson a global leader in oncology innovation and multiple myeloma treatment, has announced encouraging topline results from the Phase 3 MajesTEC-9 clinical…